501. Misbranding of Myasthene Tablets. U. S. v. 183 Bottles of Myastbene Tablets (and 1 other seizure action against Myasthene Tablets). Default deerces of condemnation and destruction. (F. D. C. Nos. 24S3, 2643. Sample Nos. 1676-E, 1677-E, 1678-E, 28932-E.) On August 2 and 21,1940, the United States attorney for the District of Colum- bia filed libels against 326 bottles of Myasthene Tablets at Washington, D. C, alleging that 183 of said bottles had been shipped in interstate commerce on or about March 30,1940, by the Medicinal Specialties Co. from New York, N. Y., and that 143 were being offered for sale in the District of Columbia at various branches of the Whelan Drug Co., Inc.; and charging that the article was misbranded. Analysis showed that it contained 7.5 grains of aminoacetic acid (glycocoll) per tablet. It was alleged to be misbranded in that representations in the labeling that it would increase the chemical source of muscular energy, would increase muscle phosphocreatine in the system when a deficiency existed, would provide energy for muscle action, would relieve tiredness or fatigue, would be efficacious in the treatment of muscular ailments, including mild muscular debility; and in that representations in the labeling of a portion of the article that it would check tiredness, pep up muscles, and give the user an amazing feeling of strength, that it would relieve weakness, exhaustion, run-down conditions, and lack of pep and appetite, that it would produce amazing results in conditions of overwork and of protein deficiency, would increase the chemical source of energy for muscular action right in the muscles themselves, that it would combat certain poisonous substances which ordinarily may be harmful, and would give the user vim, vigor, pep, and energy, were false and misleading, since it would not be efficacious for such purposes. On March 14, 1941, the claim and answer of the Medicinal Specialties Co. having been withdrawn, judgments of condemnation were entered and the product was ordered delivered to the Food and Drug Administration for technical uses.